DNTH Dianthus Therapeutics, Inc. /DE/
Pharmaceutical Preparations · Nasdaq · SEC CIK 1690585 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-67.3%
TTM net income YoY-91.1%
TTM EPS YoY-64.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-8,739.3%
Net margin-7,973.3%
FCF margin-6,349.4%
EBITDA margin-8,733.9%
Returns
ROE-38.4%
ROA-35.9%
ROIC (approx.)-36.4%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets7.1%
Debt / equity0.00x
Current ratio13.32x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue10.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.04M | $6.24M | $2.83M | — | — |
| R&D expense | $145.64M | $83.11M | $32.84M | $29.38M | $46.77M |
| SG&A expense | $34.33M | $24.99M | $18.16M | $6.74M | $27.93M |
| Operating income | -$177.93M | -$101.86M | -$48.17M | -$29.70M | -$74.69M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$162.34M | -$84.97M | -$43.55M | -$28.48M | -$71.14M |
| EBITDA | -$177.82M | -$101.77M | -$48.11M | -$29.68M | -$72.67M |
| EPS (basic) | -4.20 | -2.55 | -8.45 | -32.57 | -1.29 |
| EPS (diluted) | -4.20 | -2.55 | -8.45 | -32.57 | -1.29 |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | — | — |
| Weighted avg. shares (diluted) | 38.62M | 33.31M | 5.15M | 874,234 | 54.95M |
| Balance sheet | |||||
| Cash & equivalents | $51.09M | $23.02M | $132.39M | $15.43M | $7.64M |
| Short-term investments | $353.21M | $252.45M | $41.39M | $60.12M | $45.28M |
| Receivables | $52,000 | $0 | $294,000 | $4.70M | — |
| Current assets | $409.44M | $280.90M | $177.45M | $82.03M | $180.69M |
| PP&E, net | $296,000 | $194,000 | $185,000 | $142,000 | $7.46M |
| Total assets | $530.92M | $374.01M | $179.41M | $83.11M | $189.93M |
| Current liabilities | $30.73M | $18.45M | $9.63M | $8.22M | $10.86M |
| Total liabilities | $37.52M | $21.53M | $10.54M | $9.45M | $17.26M |
| Shareholders' equity | $493.40M | $352.48M | $168.87M | -$44.37M | -$17.25M |
| Shares outstanding | 43.22M | 31.12M | 14.82M | 875,279 | 58.80M |
| Cash flow statement | |||||
| Operating cash flow | -$129.06M | -$78.18M | -$36.86M | -$29.07M | -$59.53M |
| Capital expenditure | $213,000 | $105,000 | $110,000 | $139,000 | $1.26M |
| Free cash flow | -$129.27M | -$78.28M | -$36.97M | -$29.21M | -$60.80M |
| Investing cash flow | -$122.83M | -$286.81M | $20.25M | -$59.82M | $43.43M |
| Financing cash flow | $280.12M | $255.62M | $133.57M | $96.68M | $89.60M |
| Depreciation & amortization | $111,000 | $96,000 | $67,000 | $30,000 | $2.02M |
| Stock-based compensation | $22.79M | $12.89M | $2.90M | $1.52M | $10.31M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.